ArticleMethods in molecular biology (Clifton, N.J.)2025
Production and Purification of Recombinant SUMOylation Enzymes and SUMO Proteins.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SUMO proteins are post-translational modifiers of the ubiquitin family, which are conjugated to thousands of target proteins, modifying their function or fate. SUMOylation involves a SUMO-E1 activating enzyme (Sae1/Sae2 heterodimer), a SUMO E2 conjugating enzyme (Ubc9), and, in some cases, SUMO E3s. Several deSUMOylases can remove the conjugated SUMO from the target, making SUMOylation an extremely dynamic process.The in vitro reconstitution of SUMOylation reaction using purified SUMO, E1, and E2 enzymes is a powerful tool for analyzing the effects of SUMOylation on specific target proteins, identifying novel regulators of SUMO conjugation/deconjugation, and screening for molecules that modulate this pathway. While these components are commercially available, their expression in E. coli and subsequent purification offers the possibility to produce large quantities, which can be required for high-throughput screening, structural, or biophysical approaches. In this protocol, we present optimized procedures for the production and purification of SUMO and the SUMO E1 and E2 enzymes, as well as an assay to control their activity.
Indexed as
Identifiers
40875122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.